Orchid Pharma Limited · NSE:ORCHPHARMA
Orchid Pharma — Q1 FY2023 Earnings Presentation
29 slides from Orchid Pharma's earnings presentation, Aug 10, 2022
Slide 1: Cover letter to stock exchanges on investor presentation
OrchidPharma¥ ( Formerly known as Orchid Chemicals & Pharmaceuticals Limited ) Corp. Off.: Orchid Pharma Ltd., ‘Orchid Towers’ 313, Valluvarkottam High Road, Nungambakkam, Chennai - 600 034. India. CIN: L24222TN1992PLC022994 10" August, 2022 National Stock Exchange of India Ltd BSE Limited Listing D
Slide 2: Investor Presentation – August 2022
Pharmay” cmt Group Company — (BSE : 524372; NSE: ORCHPHARMA) Investor Presentation — August 2022 i
Slide 3: Safe Harbor
SAFE HARBOR OrchidPharma — A Dhanuka Group Company — This presentation and the accompanying slides (the “Presentation”), which have been prepared by Orchid Pharma Ltd (the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to
Slide 4: Q1FY23 Performance Overview
Slide 5: Q1FY23 Performance Highlights
Q1FY23 Performance Highlights OrchidPharma? — A Dhanuka Group Company — Q1FY23 Key Financial Overview (Y-o-Y) I I F Revenue I Gross Profits 36.7% EBITDA EBITDA of 131.0 Crs 41.9% | I 61.2 Crs 12.4 Crs (0.4) Crs I I Key Developments * Orchid Bio-Pharma Ltd, WoS of OPL, has received approval for PLI S
Slide 6: Q1FY23 Consolidated Financials
Q1FY23 Consolidated Financials OrchidPharma? — A Dhanuka Group Company — Revenues (Rs. Crs) Gross Profit (Rs. Crs) & Margin (%) EBITDA (Rs. Crs) & Margin (%) 48.2% 42.8% 46.7% - 14.4% 9.5% 178.1 76.2 25.6 131.0 44.5 92.3 12.4 -0.4 Q1 FY22 Q4 FY22 Q1 FY23 Q1 FY22 Q4 FY22 Q1 FY23 Q1 FY22 Q4 FY22 Q1 FY
Slide 7: Quarterly Profit and Loss Statement
Quarterly Profit and Loss Statement OrchidPharma? — A Dhanuka Group Company — Particulars (Rs.Crs ) Q1FY23 Q1FY22 Q4FY22 Revenue from Operations 131.0 92.3 41.9% 178.1 -26.5% Cost of Materials consumed 111.5 67.8 98.8 Changes in Inventories -41.7 -20.0 3.2 Total Raw Material 69.8 47.8 102.0 Value Ad
Slide 8: Company Overview
Slide 9: Company Overview
Company Overview OrchidPharma? — A Dhanuka Group Company — DHANUKA GROUP PIONEER IN CEPHALOSPORIN ANTIBIOTICS ¥ Diversified group with interests in Pharmaceuticals and Crop Care with a * R&D Focused, Inventor of Enmetazobactam — First NCE invented in India. combined Mcap* of ~S 564 Mn & Total Sales
Slide 10: Dhanuka Group acquired Orchid Pharma in 2020
Dhanuka Group acquired Orchid Pharma in 2020 OrchidPharma? — A Dhanuka Group Company — 1992 2005 2008 2009 = Orchid was formed = First USFDA Approval = First ANDA Approval = First Para-lV filing for Pip-Taz in = FDF Facility Inaugurated by Dr. APJ = Partnership with Merck for collaboration with Apot
Slide 11: Background of Dhanuka Group
Background of Dhanuka Group OrchidPharma? — A Dhanuka Group Company — DHANUKA AGRITECH LTD ) ( DHANUKA LABORATORIES LTD ¢ Flagship of the Group founded in 1980 ¢ Pharmaceutical arm started in 1998. * Listed on Stock Exchanges for 35 years * Leader in Cephalosporin Antibiotics with a Market Cap of US
Slide 12: Why Orchid Pharma?
Slide 13: Experienced Board & Management Team
Experienced Board & Management Team OrchidPharma? — A Dhanuka Group Company — Mr. Ram Gopal Agarwal Mr. Manish Dhanuka Mr. Arun Dhanuka Mr. Mridul Dhanuka Chairman and Non-Executive Non-Executive Director Whole-Time Director Managing Director Director Visionary Leader at the helm of Chemical Enginee
Slide 14: Largest integrated Cephalosporin API company
Largest integrated Cephalosporin API company Pharma —A Group Company — Orehic BD) era Orchid Pharma Ltd. among _ India’s leading pharmaceutical players Vertically integrated with credentials in research, manufacturing and marketing Operations cover the entire pharmaceutical value chain from discover
Slide 15: State of the Art Manufacturing with Zero Discharge
State of the Art Manufacturing with Zero Discharge —A Pharmar Group Company — = * Integrated facilities from Intermediate to finished — 60 Acre * Sterile — 3 Lines Sterile Crystalline and 1 Lyophilized * Oral—7 Blocks with multiple lines *« Intermediates — 5 Blocks with multiple lines * Total Capaci
Slide 16: Widest range of Cephalosporins
Widest range of Cephalosporins OrchidPharma? — A Dhanuka Group Company — GENERATION 6 GENERATION 4 @--------- ‘ om f y STERILE * Cefepime + Enmetazobactam STERILE * Ceftazidime + Avibactam 4 ORAL t I I I I I I I I ¢ Cefadroxil ¢ Cefalexin ¢ Cefradine STERILE ¢ Cefalonium ¢ Cefalothin ORAL * * Cefpro
Slide 17: Strong R&D capabilities
Strong R&D capabilities —A Pharma¥ Group Company — 1m l ao ‘a Preparative HPLC TGA wr Orchid pharma has been focused on R&D, will continue to invest in it : LeMS/MS NMR (Multinuclear) ANALYTICAL R&D Powder XRD DSC Several patents granted (or under grant), of more than 900 patents filed international
Slide 18: Global presence with a wide Customer base
Global presence with a wide Customer base OrchidPharma? — A Dhanuka Group Company — Revenue Breakup by Geography (FY-22) 3% 7% 2% 4 ® Africa 29% @ Asia = Europe = North America = South America = India 17
Slide 19: First product invented in India: Enmetazobactum
First product invented in India OrchidPharma? — A Dhanuka Group Company — ENMETAZOBACTUM * In 2013, Orchid out licensed a NCE Enmetazobactam to Allecra Therapeutics, Germany for Clinical Trials. Cleared the Phase 3 trials in October 2020. * This is a Unique Beta Lactamase Inhibitor, in combination w
Slide 20: The year of turnaround
Slide 21: Progress of Turnaround
Progress of Turnaround OrchidPharma? — A Dhanuka Group Company — .since acquisition Record Revenues of Rs. 560 Crs 688 50 53 in FY22 600 560 508 450 . Record EBITDA of Rs. 53 Crs in FY22 FY18 Fy19 FY20 FY21 FY22 FY18 Fy19 FY20 FY21 FY22 Product — Market Mix Term Debt reduced by Rs. 279 Crs 427 348 M
Slide 22: Merger of Dhanuka Laboratories with Orchid
Merger of Dhanuka Laboratories with Orchid OrchidPharma’ — A Dhanuka Group Company — OPTIMIZATION OF DIVERSIFICATION ALIGNMENT OF CAPACITIES INTO NPNC APIS R&D STRENGTHS » Common RM and DLL - Ozonation » DMFs of Orchid » Optimal use of » Access to each Vendors. Higher facility, to be used site trans
Slide 23: Corporate structure post acquisition by Dhanuka Group
Corporate structure post acquisition by Dhanuka Group OrchidPharma? — A Dhanuka Group Company — CURRENT SHAREHOLDING PATTERN POST-SCHEME Dhanuka Public SHAREHOLDING PATTERN OF Group ORCHID PHARMA 70% 30% OrchidPharma? HOLDING HOLDING <a anuka — A Dhanuka Group Company — DLC wala ake Dhanuka Group (M
Slide 24: Profit and Loss Statement
Profit and Loss Statement OrchidPharma? — A Dhanuka Group Company — JeecDu a (ebm OC FY22 FY21 FY20 FY19 FY18 Total Revenue 559.6 450.1 483.8 600.0 687.8 Cost of Material Consumed 340.6 245.6 221.2 262.8 341.4 Change in Inventories of finished goods and Work in progress -27.1 -17.1 -18.3 26.6 7.6 Pu
Slide 25: Balance sheet - Assets (1/2)
Balance sheet - Assets (1/2) OrchidPharma? — A Dhanuka Group Company — ASSET (Rs. Crs.) Non - Current Assets Property, plant and equipment 583.4 670.1 843.7 1,140.6 1,268.3 Capital work-in-progress 9.8 7.4 15.1 263.8 257.2 Intangible Assets 0.3 0.4 14.2 115.7 117.9 Intangible Assets under developmen
Slide 26: Balance sheet - Equity & Liabilities (2/2)
Balance sheet - Equity & Liabilities (2/2) OrchidPharma? — A Dhanuka Group Company — EQUITY & LIABILITIES (Rs. Crs.) Mar-21 Mar-20 Equity Equity Share Capital 40.8 40.8 40.8 89.0 89.0 Other Equity 606.6 612.1 725.2 -793.0 -880.7 Total Equity 647.4 ete Ane) 766.0 -704.0 -791.8 Liabilities Non - Curre
Slide 27: Cash Flow Statement
Cash Flow Statement OrchidPharma? — A Dhanuka Group Company — Cash Flow Statement (Rs. Crs.) Profit before Tax -2.0 -116.5 -131.1 69.4 -399.0 Adjustment for Non-Operating Items -36.8 -172.2 -139.6 -57.3 -453.5 Operating Profit before Working Capital Changes 33.4 55.6 8.5 126.7 54.5 Changes in Workin
Slide 28: Awards and Accolades
Awards and Accolades OrchidPharma? — A Dhanuka Group Company — KK KA KA KA KA 2022 2013 2012 2011 2011 Awarded IGCW - 2011 Green Recognised as a Three Star Received EXIM Achievement Received EXIM Achievement Award Alathur facility was awarded Innovation Award for the Export House by the Ministry of
Slide 29: Thank you
Thank you OrchidPharma? — A Dhanuka Group Company — Orchid Pharma Ltd CIN : L24222TN1992PLC022994 Mr. Sunil Gupta- Chief Financial Officer OrchidPharma? sunilgupta@orchidpharma.com — A Dhanuka Group Company — c Mr. Irfan Raeen +91 97737 78669 irfan.raeen@linkintime.co.in orient capital her Ashish Ch